COMMUNIQUÉS West-GlobeNewswire

Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares
13/11/2025
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the [...]
Inventiva annonce les modalités définitives ainsi que l'extension de l'offre au public d'American Depositary Shares d'approximativement 150 millions de dollars
13/11/2025
Daix (France), New York City (New York, États-Unis), le 13 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
13/11/2025
Appointment Follows Israeli Ministry of Health Approval for Nexalin’s Gen-2 SYNC Device HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in [...]
Parents Say Teens are Checked Out and Need Mental Health Support, According to New Report
13/11/2025
National survey spotlights fears of tech overuse NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- A new report from BODA Therapy finds that more than 78% of parents say their teens would or might benefit from mental-health [...]
Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company
13/11/2025
Windtree and TESI signed a letter of intent for a combination of cash and securities of TESI to be paid to Windtree The companies were engaged in a potential environmental services deal for Windtree to acquire Titan [...]
HealthEquity to Enhance Member Experience with Agentic AI
13/11/2025
Nation's Largest HSA Custodian Leverages Parloa’s Advanced AI Technology to Deliver Personalized, Conversational Support for Millions of Members DRAPER, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- HealthEquity , Inc. ( [...]
Doseology Completes Extensive North American Diligence, Securing Strategic Manufacturing Agreement via U.S. Subsidiary Doseology USA Inc.
13/11/2025
KELOWNA, British Columbia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Doseology Sciences Inc. ( CSE: MOOD | PINK: DOSEF | FSE: VU70 ) (“Doseology” or the “Company”), an innovator in precision-formulated oral stimulants, is [...]
IMU Biosciences announces formation of Scientific Advisory Board
13/11/2025
PRESS RELEASE Inaugural members are highly distinguished healthcare experts in haematology, vaccinology, immunology and genetics London, UK, 13 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company [...]
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
13/11/2025
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the [...]
Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
13/11/2025
Daix (France), New York City (New York, États-Unis), le 13 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Enterome to present positive interim Phase 2 data for lead OncoMimics™ immunotherapy EO2463 in follicular lymphoma at American Society for Hematology (ASH) meeting
13/11/2025
New data from cohort 3 show EO2463 can be safely added to rituximab in first-line low-tumor-burden follicular lymphoma in need of treatment All six patients responded positively to the combination Overall response data [...]
T-Therapeutics announces Series A extension to $91 million to advance first-in-class bispecifics towards the clinic
13/11/2025
$32 million new equity injection adds to previously announced $59 million New investors Tencent and BGF joined by all existing major shareholders Funds will advance pipeline of novel TCR-CD3 bispecifics in cancer and [...]
Zealand Pharma Announces Financial Results for the First Nine Months of 2025
13/11/2025
Company announcement – No. 23 / 2025 Zealand Pharma Announces Financial Results for the First Nine Months of 2025 With petrelintide advancing at full speed and topline data rapidly approaching for both petrelintide and [...]
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
13/11/2025
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing [...]
Caring Brands Announces Pricing of $4,000,000 Million Uplisting to Nasdaq
13/11/2025
FORT PIERCE, Fla., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Caring Brands, Inc. (“Caring Brands” or the “Company”), a wellness consumer products company offering several over-the-counter (OTC) and cosmetic consumer products, [...]
Aurora Spine Corporation Announces Participation at the North American Spine Society Annual Meeting
13/11/2025
Company to Showcase Cutting-Edge Innovations at Booth #1622 CARLSBAD, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a leader in the [...]
Anteris Announces Results for the Third Quarter of 2025
12/11/2025
MINNEAPOLIS, Minn. and BRISBANE, Australia , Nov. 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to [...]
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt [...]
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
12/11/2025
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate of 97.4% based on [...]

Pages